Bayer joins Sensyne Health consortium for accelerating new medicine discovery

pharmatimes | May 03, 2019

Bayer joins Sensyne Health consortium for accelerating new medicine discovery
Sensyne Health and Bayer have announced that Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capability. Microsoft, EY, JP Morgan, and Peel Hunt are already in the consortium. Under the terms of the agreement, Bayer will work with Sensyne Health and the consortium members as they develop proposals to scale Sensyne Health’s current network of strategic research agreements with NHS Trusts, aiming to accelerate the discovery and development of new medicines and improve patient care through the analysis of large databases of anonymised patient data, using clinical artificial intelligence. Sensyne Health and its consortia of experts have the requisite capabilities in clinical AI, computing, data analytics, systems integration, business planning, investment banking and, with the addition of Bayer, the relevant pharmaceutical R&D expertise and capability.

Spotlight

There are eight common blood types. Keyword there? Common. If what you know about blood stops right around there, then this is all going to escalate very quickly. There are literally millions of varieties of blood types, and the rarest one is shared by fewer than 45 people on Earth. Talk about exclusive.

Spotlight

There are eight common blood types. Keyword there? Common. If what you know about blood stops right around there, then this is all going to escalate very quickly. There are literally millions of varieties of blood types, and the rarest one is shared by fewer than 45 people on Earth. Talk about exclusive.

Related News

PHARMA TECH

Tranquilmoney Releases PharmTracker for Independent Pharmacies, Small and Medium Pharmacy Chains

Tranquilmoney | December 28, 2020

Tranquilmoney, Inc., an organization that oversaw drug store outsider case compromise for Costco Pharmacy for more than 20 years, has delivered an electronic adaptation of its product. Any drug store would now be able to join to PharmTrackerTM and begin utilizing the framework to handle their cases. Tranquilmoney has overseen over $1 billion per year in drug store receivables compromise with 100% compromise and 99.9% assortments. Industry guidelines of assortment are about 92.5%. Dr. Karun Philip, Chairman and CEO, says "Drug store claims are moderately little with a normal of $40 from the protection plans. More than 20 years, we built up a framework that consolidated Artificial Intelligence, enormous information stockrooms, and area specialists, that in blend permit us to coordinate each installment to its relating guarantee. Thusly, all non-installments are recognized, and an underpayment of even one penny is identified and can be rebilled." PharmTrackerTM can be utilized as a self-administration programming on the web or as a reevaluated administration. Utilizing Tranquiilmoney's framework will help a Pharmacy gather as much as 99.9% from protection, more than the business standard of about 92.5%. Tranquilmoney expenses start at 45 pennies for every case for at least 3000 cases for each month going down to 2 pennies a case for bigger volumes. Here is the finished value list.

Read More

PHARMACY MARKET

Virpax Announces MMS019 Manufacturing and Supply Agreement

Virpax Pharmaceuticals | August 27, 2021

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for Virpax’s clinical studies as well as the long-term commercial supply of MMS019. Seqens will conduct process development and validation of additional large scale commercial quantities of MMS019 at its facilities in Devens and Newburyport, Massachusetts. “Establishing a collaboration with a strong partner capable of supplying clinical and commercial scale quantities of MMS019 is another important advancement in our MMS019 product development strategy. Seqens has a demonstrated expertise in developing and manufacturing highly-complex molecules for large scale production,” said Anthony Mack, Chairman and CEO of Virpax. “Importantly, we expect this collaboration to support future development and supply additional Molecular Envelope Technology programs under development, including Envelta™ and PES200, our post-traumatic stress disorder product candidate,” concluded Mr. Mack. About MMS019 MMS019 is a drug product candidate based on a type of nanotechnology that enables the exclusive delivery of a metabolically labile peptide drug into the brain via intranasal delivery. MMS019 is manufactured using industrially relevant equipment and processes (high pressure homogenization and spray drying). There is pharmacological evidence of activity of molecular envelope technology (MET) enabled enkephalin in morphine-tolerant animals. The MET nanoparticles are well tolerated via the nasal route at the dose administered. MMS019 demonstrated comparable preclinical activity to morphine in all animal pain models tested without the drug seeking and tolerance associated with opioids. About Seqens SEQENS is an integrated global leader in pharmaceutical solutions and specialty ingredients. With 24 production sites and 7 R&D centers in Europe, North America and Asia, SEQENS develops and manufactures tailor-made solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and home care. Driven by a culture of excellence and a strong entrepreneurial spirit, our 3,200 employees are committed to providing our customers with the highest level of service and quality while acting ethically in accordance with our corporate social responsibility program.” About Virpax Pharmaceuticals Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2.

Read More

PHARMACY MARKET

EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV)

CureVac, EMA | February 18, 2021

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit information as it opens up, beginning with the preclinical and beginning stage proof presently submitted. As opposed to a customary advertising authorisation application, in which all information on a medication's or immunization's viability, security and quality and all necessary archives should be prepared toward the beginning of the assessment. Continuous preliminaries are proceeding to assess the immunization's wellbeing, immunogenicity and viability against COVID-19. EMA will assess information from these and other clinical preliminaries as they become accessible. The moving audit will proceed until the CHMP concludes that adequate information is accessible for a conventional showcasing authorisation application. Because of the work attempted in the moving audit, it should take less time than typical to assess such an application. EMA will survey the immunization's consistence with the typical norms for adequacy, wellbeing and drug quality inside the moving audit measure. About CVnCoV CVnCoV is an mRNA vaccine which encodes the SARS-CoV-2 Spike (S) protein. The mRNA sequence is formulated in minute lipid particles to prevent it from being broken down too quickly. When a person receives the vaccine, some of their cells will use the mRNA molecules to temporarily produce the S protein. This activates the person’s immune system, priming it to respond more quickly to a subsequent SARS-CoV-2 infection.

Read More